-
Something wrong with this record ?
PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design
K. Broglio, L. Kostakoglu, C. Ward, F. Mattiello, D. Sahin, T. Nielsen, A. McGlothlin, CF. Elliott, T. Witzig, LH. Sehn, M. Trnĕný, U. Vitolo, M. Martelli, M. Foster, B. Wendelberger, G. Nowakowski, DA. Berry
Language English Country United States
Document type Meta-Analysis, Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Bayes Theorem MeSH
- Biomarkers analysis MeSH
- Lymphoma, Large B-Cell, Diffuse * diagnostic imaging drug therapy MeSH
- Clinical Trials as Topic MeSH
- Humans MeSH
- Disease-Free Survival MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Meta-Analysis MeSH
- Research Support, Non-U.S. Gov't MeSH
This study's focus is the association of end-of-therapy (EOT) PET results with progression-free (PFS) and overall survival (OS) in patients with diffuse large B-cell lymphoma receiving first-line chemoimmunotherapy. We develop a Bayesian hierarchical model for predicting PFS and OS from EOT PET-complete response (PET-CR) using a literature-based meta-analysis of 20 treatment arms and a substudy of 4 treatment arms in 3 clinical trials for which we have patient-level data. The PET-CR rate in our substudy was 72%. The modeled estimates for hazard ratio (PET-CR/non-PET-CR) were 0.13 for PFS (95% CI 0.10, 0.16) and 0.10 for OS (CI 0.07, 0.12). Hazard ratios varied little by patient subtype and were confirmed by the overall meta-analysis. We link these findings to designing future clinical trials and show how our model can be used in adapting the sample size of a trial to accumulating results regarding treatment benefits on PET-CR and a survival endpoint.
BC Cancer Agency Vancouver BC Canada
Berry Consultants LLC Austin TX USA
Candiolo Cancer Institute FPO IRCCS Candiolo Italy
Charles University and General University Hospital Prague Czech Republic
Department of Nuclear Medicine University of Virginia Charlottesville VA USA
Department of Translational and Precision Medicine Sapienza Università di Roma Rome Italy
F Hoffmann La Roche Ltd Basel Switzerland
University Libraries Texas A and M University College Station TX USA
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22032498
- 003
- CZ-PrNML
- 005
- 20230131150634.0
- 007
- ta
- 008
- 230120s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/10428194.2022.2095624 $2 doi
- 035 __
- $a (PubMed)35815677
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Broglio, Kristine $u Berry Consultants, LLC, Austin, TX, USA $1 https://orcid.org/0000000284053702
- 245 10
- $a PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design / $c K. Broglio, L. Kostakoglu, C. Ward, F. Mattiello, D. Sahin, T. Nielsen, A. McGlothlin, CF. Elliott, T. Witzig, LH. Sehn, M. Trnĕný, U. Vitolo, M. Martelli, M. Foster, B. Wendelberger, G. Nowakowski, DA. Berry
- 520 9_
- $a This study's focus is the association of end-of-therapy (EOT) PET results with progression-free (PFS) and overall survival (OS) in patients with diffuse large B-cell lymphoma receiving first-line chemoimmunotherapy. We develop a Bayesian hierarchical model for predicting PFS and OS from EOT PET-complete response (PET-CR) using a literature-based meta-analysis of 20 treatment arms and a substudy of 4 treatment arms in 3 clinical trials for which we have patient-level data. The PET-CR rate in our substudy was 72%. The modeled estimates for hazard ratio (PET-CR/non-PET-CR) were 0.13 for PFS (95% CI 0.10, 0.16) and 0.10 for OS (CI 0.07, 0.12). Hazard ratios varied little by patient subtype and were confirmed by the overall meta-analysis. We link these findings to designing future clinical trials and show how our model can be used in adapting the sample size of a trial to accumulating results regarding treatment benefits on PET-CR and a survival endpoint.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a Bayesova věta $7 D001499
- 650 _2
- $a klinické zkoušky jako téma $7 D002986
- 650 12
- $a difúzní velkobuněčný B-lymfom $x diagnostické zobrazování $x farmakoterapie $7 D016403
- 650 _2
- $a biologické markery $x analýza $7 D015415
- 655 _2
- $a metaanalýza $7 D017418
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kostakoglu, Lale $u Department of Nuclear Medicine, University of Virginia, Charlottesville, VA, USA $1 https://orcid.org/0000000154788161
- 700 1_
- $a Ward, Carol $u F. Hoffmann-La Roche Ltd., Basel, Switzerland $1 https://orcid.org/0000000199947963
- 700 1_
- $a Mattiello, Federico $u F. Hoffmann-La Roche Ltd., Basel, Switzerland
- 700 1_
- $a Sahin, Denis $u F. Hoffmann-La Roche Ltd., Basel, Switzerland $1 https://orcid.org/0000000312142447
- 700 1_
- $a Nielsen, Tina $u F. Hoffmann-La Roche Ltd., Basel, Switzerland
- 700 1_
- $a McGlothlin, Anna $u Berry Consultants, LLC, Austin, TX, USA $1 https://orcid.org/0000000290796166
- 700 1_
- $a Elliott, Corrine F $u Berry Consultants, LLC, Austin, TX, USA $1 https://orcid.org/0000000179359945
- 700 1_
- $a Witzig, Thomas $u Mayo Clinic, Rochester, MN, USA $1 https://orcid.org/0000000242156500
- 700 1_
- $a Sehn, Laurie H $u BC Cancer Agency, Vancouver, BC, Canada $1 https://orcid.org/0000000318609765
- 700 1_
- $a Trnĕný, Marek $u Charles University and General University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000269526073
- 700 1_
- $a Vitolo, Umberto $u Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy $1 https://orcid.org/0000000177722747
- 700 1_
- $a Martelli, Maurizio $u Department of Translational and Precision Medicine, Sapienza Università di Roma, Rome, Italy $1 https://orcid.org/0000000310070339
- 700 1_
- $a Foster, Margaret $u University Libraries, Texas A&M University, College Station, TX, USA $1 https://orcid.org/0000000244537788
- 700 1_
- $a Wendelberger, Barbara $u Berry Consultants, LLC, Austin, TX, USA $1 https://orcid.org/0000000344269602
- 700 1_
- $a Nowakowski, Grzegorz $u Mayo Clinic, Rochester, MN, USA
- 700 1_
- $a Berry, Donald A $u Berry Consultants, LLC, Austin, TX, USA $1 https://orcid.org/0000000276573871
- 773 0_
- $w MED00003140 $t Leukemia & lymphoma $x 1029-2403 $g Roč. 63, č. 12 (2022), s. 2816-2831
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35815677 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131150630 $b ABA008
- 999 __
- $a ok $b bmc $g 1891325 $s 1183833
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 63 $c 12 $d 2816-2831 $e 20220711 $i 1029-2403 $m Leukemia & lymphoma $n Leuk Lymphoma $x MED00003140
- LZP __
- $a Pubmed-20230120
